Peter J. Allen
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays for early disease detection. We hypothesized that PDAC cell subpopulations could be identified by aberrant glycan signatures in both tumor tissue and blood samples. We used multiplexed glycan immunofluorescence to distinguish between PDAC and noncancer cell subpopulations within tumor tissue, and we developed hybrid glycan sandwich assays to determine whether the aberrant glycan signatures could be detected in blood samples. We found that PDAC cells were identified by signatures of glycans detected by four glycan-binding proteins (VVL, CA19-9, sTRA, and GM2) and that there are three types of glycan-defined PDAC tumors: sTRA type, CA19-9 type, and intermixed. In patient-matched tumor and blood samples, the PDAC tumor type could be determined by the aberrant glycans in the blood. As a result, the combined assays of aberrant glycan signatures were more sensitive and specific than any individual assay. Our results demonstrate a methodology to detect and stratify PDAC.
Year:
2025
Purpose: Intraductal papillary mucinous neoplasms (IPMN) occur in 5% to 10% of the population, but only a small minority progress to pancreatic ductal adenocarcinoma (PDAC). The lack of accurate predictors of high-risk disease leads to both unnecessary operations for indolent neoplasms and missed diagnoses of PDAC. Digital spatial RNA profiling (DSP-RNA) provides an opportunity to define and associate transcriptomic states with cancer risk. Experimental Design: We performed whole-transcriptome DSP-RNA profiling on 10 IPMN specimens encompassing the spectrum of dysplastic changes from normal duct to cancer. Epithelial regions within each tissue were annotated as normal duct, low-grade dysplasia, high-grade dysplasia, or invasive carcinoma. The resulting digital gene expression data were analyzed with R/Bioconductor. Results: Our analysis uncovered three distinct epithelial transcriptomic states—“normal-like” ( cNL ), “low risk” ( cLR ), and “high risk” ( cHR )—which were significantly associated with pathologic grade. Furthermore, the three states were significantly correlated with the exocrine, classical, and basal-like molecular subtypes described in PDAC. Specifically, exocrine function diminished in cHR , classical activation distinguished neoplasia ( cLR and cHR ) from cNL , and basal-like genes were specifically upregulated in cHR . Intriguingly, markers of cHR were detected in normal duct and low-grade dysplasia regions from specimens with PDAC but not from specimens containing only low-grade IPMN. Conclusions: DSP-RNA of IPMN revealed low-risk (indolent) and high-risk (malignant) expression programs that correlated with the activity of exocrine and basal-like PDAC signatures, respectively, and distinguished pathologically low-grade specimens from malignant specimens. These findings contextualize IPMN pathogenesis and have the potential to improve risk stratification.
Year:
2025
Table S1: Gene Sets; Table S2: Patient Clinical Information; Table S3: Clustering Results; Table S4: Differential expression analysis between clusters (full dataset); Table S5: GSEA results (full dataset); Table S6: Stromal highly variable genes; Table S7: DE analysis of NL-LGD subset; Table S8: GSEA results (NL-LGD subset); Table S9: Validation dataset clustering results
Year:
2025
Figure S1: Hematoxylin and eosin (H&E) stained tissue images from patient p10 corresponding to Figure 1B; Figure S2: Quality control of DSP-RNA data; Figure S3: AOI Filtering Criteria; Figure S4: Gene Filtering Criteria; Figure S5: Normalization of DSP-RNA data; Figure S6: Dimension reduction analysis of DSP-RNA data; Figure S7: Immunofluorescent staining of epithelial marker genes; Figure S8: GSEA analysis comparing IPMN clusters to PDAC molecular subtyping studies; Figure S9: Leading edge analysis of GSEA results; Figure S10: Hallmark pathways associated with IPMN transcriptomic states; Figure S11: Analysis of adjacent stromal (PanCK-, CD3-, CD45-) AOIs; Figure S12: GSEA analyses of NL-LGD AOIs; Figure S13: Quality control of external DSP-RNA datasets incorporated for validation; Figure S14: PCA projection of validation datasets; Figure S15: GSEA and GSVA of the Carpenter and colleagues dataset
Year:
2025
The histopathologic heterogeneity of intraductal papillary mucinous neoplasms (IPMN) complicates the prediction of pancreatic ductal adenocarcinoma (PDAC) risk. Intratumoral regions of pancreaticobiliary (PB), intestinal (INT), and gastric foveolar (GF) epithelium may occur with either low-grade dysplasia (LGD) or high-grade dysplasia (HGD). We used digital spatial RNA profiling of dysplastic epithelium (83 regions) from surgically resected IPMN tissues (12 patients) to differentiate subtypes and predict genes associated with malignancy. The expression patterns of PB and GF lesions diverged from INT, suggesting that PB and GF arise from a common lineage. Transcriptional dysregulation within PB lesions mirrored that of PDAC, whereas INT and GF foci did not. Tumor necrosis factor/nuclear factor κB (TNF-NFκB) and cell cycle (cycling S and cycling G 2 -M) programs occurred with relative prominence in PB and INT subtypes, respectively. Together, this study delineates markers of high-risk IPMN and insights into malignant progression.
Year:
2023
Collaborators (8)
Brian Haab
Professor
Van Andel Institute
Arul M Chinnaiyan
University of Michigan
Marina Pasca Di Magliano
Associate Professor
University of Michigan
Ying Huang
Fred Hutchinson Cancer Research Center
Benjamin Staal
Van Andel Institute
Fengming Chen
Duke University Medical Center
Timothy Frankel
Assistant Professor
University of Michigan Hospital
Chanjuan Shi
Professor
Duke University
Make your next move.
Prepare your application
Review drafts before you send them.